trastuzumab deruxtecan
daiichi sankyo,astrazeneca
['bcsm']
db03: safety update no new safety signals with tdxd no additional grade 3 ild events most traes were grade 1/2 note that risks of n/v, fatigue and alopecia were higher with tdxd, particularly in initial cycles #asco2022 #bcsm 
Breast Medical Oncologist @UNC_Lineberger Prior @JCO_ASCO editorial fellow. Views are my own.